Multimarker real-time reverse transcription-PCR for quantitative detection of melanoma-associated antigens: A novel possible staging method

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 1, 2008, Pages 56-64

  Arenberger, P ^a   Arenbergerova, M ^a   Gkalpakiotis, S ^a   Lippert, J ^a   Stribrna, J ^a   Kremen, J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Circulating melanoma cells; Detection; Malignant melanoma; Melanoma markers; Real time RT PCR

Indexed keywords

ALPHA2A INTERFERON; GLYCOPROTEIN GP 100; MELAN A; MELANOMA ANTIGEN 3; MONOPHENOL MONOOXYGENASE; TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER RELAPSE; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MELANOMA; MELANOMA CELL; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; NEOPLASM STAGING; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 37749044355     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02329.x     Document Type: Article

References (37)

1. Hoon DS, Wang Y, Dale PS et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995; 13: 2109-2116.
2. Mocellin S, Del Fiore P, Guarnieri L et al. Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int J Cancer 2004; 111: 741-745.
3. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991; 338: 1227-1229.
4. Berking C, Schlüpen EM, Schrader A, Atzpodien J, Volkenandt M. Tumor markers in peripheral blood of patients with malignant melanoma. Multimarker RT-PCR versus a luminoimmunometric assay for S-100. Arch Dermatol Res 1999; 291: 479-484.
5. Blaheta HJ, Paul T, Sotlar K et al. Detection of melanoma cells in sentinel lymph nodes, bone marrow and peripheral blood by a reverse transcription-polymerase chain reaction assay in patients with primary cutaneous melanoma: Association with Breslow's tumour thickness. Br J Dermatol 2001; 145: 195-202.
6. Curry BJ, Myers K, Hersey P. MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. J Clin Oncol 1999; 17: 2562-2571.
7. Foss AJ, Guille MJ, Occleston NL, Hykin PG, Hungerford JL, Lightman S. The detection of melanoma cells in peripheral blood by reverse transcription polymerase chain reaction. Br J Cancer 1995; 72: 155-159.
8. Ghossein RA, Coit D, Brennan M et al. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. Clin Cancer Res 1998; 4: 419-428.
9. Hanekom GS, Stubbings HM, Johnson CA, Kidson SH. The detection of circulating melanoma cells correlates with tumour thickness and ulceration but is not predictive of metastasis for patients with primary melanoma. Melanoma Res 1999; 9: 465-473.
10. Le Bricon T, Stoitchkov K, Letellier S et al. Simultaneous analysis of tyrosinase mRNA and markers of tyrosinase activity in the blood of patients with metastatic melanoma. Clin Chim Acta 1999; 282: 101-113.
11. Mellado B, Del Carmen Vela M, Colomer D et al. Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. J Clin Oncol 2002; 20: 4032-4039.
12. Palmieri G, Strazzullo M, Ascierto PA, Satriano SM, Daponte A, Castello G. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group. J Clin Oncol 1999; 17: 304-311.
13. Proebstle TM, Jiang W, Högel J, Keilholz U, Weber L, Voit C. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors. Br J Cancer 2000; 82: 118-123.
14. Schittek B, Bodingbauer Y, Ellwanger U, Blaheta HJ, Garbe C. Amplification of MelanA messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma. Br J Dermatol 1999; 141: 30-36.
15. Tsukamoto K, Ueda M, Hirata S et al. gp100 mRNA is more sensitive than tyrosinase mRNA for RT-PCR amplification to detect circulating melanoma cells in peripheral blood of melanoma patients. J Dermatol Sci 2000; 23: 126-131.
16. Hoon DSB, Bostick P, Kuo C et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res 2000; 60: 2253-2257.
17. Glaser R, Rass K, Seiter S, Hauschild A, Christophers E, Tilgen W. Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: A clinical two-center study. J Clin Oncol 1997; 15: 2818-2825.
18. Jung FA, Buzaid AC, Ross MI et al. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol 1997; 15: 2826-2831.
19. Keilholz U, Goldin-Lang P, Bechrakis NE et al. Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction. Clin Cancer Res 2004; 10: 1605-1612.
20. Schuster R, Max N, Mann B et al. Quantitative real-time RT-PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers. Int J Cancer 2004; 108: 219-227.
21. Dasi F, Martinez-Rodes P, March JA et al. Real-time quantification of human telomerase reverse transcriptase mRNA in the plasma of patients with prostate cancer. Ann N Y Acad Sci 2006; 1075: 204-210.
22. Leelawat K, Leelawat S, Ratanachu-Ek T et al. Circulating hTERT mRNA as a tumor marker in cholangiocarcinoma patients. World J Gastroenterol 2006; 12: 4195-4198.
23. Mavrogiannou E, Strati A, Stathopoulou A, Tsaroucha EG, Kaklamanis L, Lianidou ES. Real-time RT-PCR quantification of human telomerase reverse transcriptase splice variants in tumor cell lines and non-small cell lung cancer. Clin Chem 2007; 53: 53-61.
24. Takihana Y, Tsuchida T, Fukasawa M, Araki I, Tanabe N, Takeda M. Real-time quantitative analysis for human telomerase reverse transcriptase mRNA and human telomerase RNA component mRNA expressions as markers for clinicopathologic parameters in urinary bladder cancer. Int J Urol 2006; 13: 401-408.
25. Balch CM, Buzaid AC, Atkins MB et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000; 88: 1484-1491.
26. Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17.600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-3634.
27. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648.
28. Brochez L, Naeyaert JM. Serological markers for melanoma. Br J Dermatol 2000; 143: 256-268.
29. Aubin F, Chtourou M, Teyssier JR et al. The detection of tyrosinase mRNA in the peripheral blood of stage I melanoma patients is not of clinical relevance in predicting metastasis risk and survival. Melanoma Res 2000; 10: 113-118.
30. Pittman K, Burchill S, Smith B et al. Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Ann Oncol 1996; 7: 297-301.
31. Reinhold U, Ludtke Handjery HC, Schnautz S, Kreysel HW, Abken H. The analysis of tyrosinase specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J Invest Dermatol 1997; 108: 166-169.
32. Stevens GL, Scheer WD, Levine EA. Detection of tyrosinase mRNA from the blood of melanoma patients. Cancer Epidemiol Biomarkers Prev 1996; 5: 293-296.
33. Sarantou TC, Hi DDJ, Garrison DA. Melanoma associated antigens as messenger RNA detection markers for melanoma. Cancer Res 1997; 57: 1371-1376.
34. Luzar B, Poljak M, Marin IJ, Eberlinc A, Klopcic U, Gale N. Human telomerase catalytic subunit gene re-expression is an early event in oral carcinogenesis. Histopathology 2004; 45: 13-19.
35. De Vries TJ, Fourkour A, Punt CJA et al. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: A quality control study using real-time quantitative RT-PCR. Br J Cancer 1999; 80: 883-891.
36. Pohlreich P, Stříbrná J, Kleibl Z, Horak V, Klaudy J. Detection of neoplastic cells in blood of miniature pigs with hereditary melanoma. Vet Med Czech 2001; 46: 199-204.
37. Mocellin S, Hoon D, Ambrosi A, Nitti D, Rossi CR. The prognostic value of circulating tumor cells in patients with melanoma: A systematic review and meta-analysis. Clin Cancer Res 2006; 12: 4605-4613.